Ascendis Pharma A/S - stock earnings
ASND Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| April 25, 2024 AfterMarket | - / -1.5324000000 | - | - / 81.1 million | - |
ASND Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -96.0 million USD | 152.2 million USD |
| 2023Q3 | -171.7 million USD | 50.9 million USD |
| 2023Q2 | -132.0 million USD | 51.5 million USD |
| 2023Q1 | -120.9 million USD | 36.6 million USD |
| 2022Q4 | -222.6 million USD | 24.6 million USD |
| 2022Q3 | -165.7 million USD | 15.0 million USD |
| 2022Q2 | -85.0 million USD | 6.4 million USD |
| 2022Q1 | -140.1 million USD | 7.6 million USD |
| 2021Q4 | -120.6 million USD | 5.6 million USD |
| 2021Q3 | -93.1 million USD | 1.3 million USD |
| 2021Q2 | -159.3 million USD | 1.2 million USD |
| 2021Q1 | -73.6 million USD | 874754 USD |
| 2020Q4 | -169.2 million USD | 651563 USD |
| 2020Q3 | -142.8 million USD | 3.2 million USD |
| 2020Q2 | -106.7 million USD | 1.6 million USD |
| 2020Q1 | -88.6 million USD | 2.8 million USD |
| 2019Q4 | -90.0 million USD | 2.8 million USD |
| 2019Q3 | -27.5 million USD | 2.5 million USD |
| 2019Q2 | -67.0 million USD | 3.7 million USD |
| 2019Q1 | -35.9 million USD | 11.8 million USD |
| 2018Q4 | -36.6 million USD | 12.0 million USD |
| 2018Q3 | -39.5 million USD | 23274 USD |
| 2018Q2 | -26.3 million USD | 20813 USD |
| 2018Q1 | -50.9 million USD | 34448 USD |
| 2017Q4 | -40.8 million USD | 334375 USD |
| 2017Q3 | -39.9 million USD | 511339 USD |
| 2017Q2 | -35.1 million USD | 508024 USD |
| 2017Q1 | -26.9 million USD | 397556 USD |
| 2016Q4 | -17.3 million USD | 1.1 million USD |
| 2016Q3 | -20.5 million USD | 1.3 million USD |
| 2016Q2 | -14.8 million USD | 1.3 million USD |
| 2016Q1 | -13.6 million USD | 2.2 million USD |
| 2015Q4 | -13.1 million USD | 2.2 million USD |
| 2015Q3 | -8.2 million USD | 2.4 million USD |
| 2015Q2 | -16.9 million USD | 2.2 million USD |
| 2015Q1 | 1.5 million USD | 2.3 million USD |
| 2014Q4 | -6.1 million USD | 3.4 million USD |
| 2014Q3 | -2.5 million USD | 4.1 million USD |
| 2014Q2 | -2.9 million USD | 5.3 million USD |
| 2014Q1 | -690350 USD | 5.5 million USD |
| 2013Q4 | 3.1 million USD | 7.7 million USD |
ASND Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -532.2 million USD | 294.8 million USD |
| 2022 | -625.9 million USD | 54.9 million USD |
| 2021 | -436.2 million USD | 8.8 million USD |
| 2020 | -510.2 million USD | 8.5 million USD |
| 2019 | -244.2 million USD | 15.0 million USD |
| 2018 | -148.8 million USD | 12.1 million USD |
| 2017 | -148.0 million USD | 1.8 million USD |
| 2016 | -72.1 million USD | 4.8 million USD |
| 2015 | -36.0 million USD | 8.9 million USD |
| 2014 | -11.7 million USD | 17.0 million USD |
| 2013 | 5.6 million USD | 28.2 million USD |
| 2012 | 1.6 million USD | 20.6 million USD |
ASND
Price: $141.01
52 week price:
Earnings Per Share: -9.19 USD
P/E Ratio: -12.10
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 126716
Ebitda: -36.5 millionMarket Capitalization: 7.7 billion